Publication
Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?
dc.contributor.author | Sahara, K | |
dc.contributor.author | Tsilimigras, D | |
dc.contributor.author | Merath, K | |
dc.contributor.author | Bagante, F | |
dc.contributor.author | Guglielmi, A | |
dc.contributor.author | Aldrighetti, L | |
dc.contributor.author | Weiss, M | |
dc.contributor.author | Bauer, T | |
dc.contributor.author | Alexandrescu, S | |
dc.contributor.author | Poultsides, G | |
dc.contributor.author | Maithel, S | |
dc.contributor.author | Pinto Marques, H | |
dc.contributor.author | Martel, G | |
dc.contributor.author | Pulitano, C | |
dc.contributor.author | Shen, F | |
dc.contributor.author | Soubrane, O | |
dc.contributor.author | Koerkamp, B | |
dc.contributor.author | Matsuyama, R | |
dc.contributor.author | Endo, I | |
dc.contributor.author | Pawlik, T | |
dc.date.accessioned | 2021-10-08T14:38:31Z | |
dc.date.available | 2021-10-08T14:38:31Z | |
dc.date.issued | 2019 | |
dc.description.abstract | Background: Although lymph node metastasis (LNM) is an important prognostic indicator for patients with intrahepatic cholangiocarcinoma (ICC), the benefit and indication for lymphadenectomy remain unclear. Methods: Patients diagnosed with ICC between 1990 and 2016 were identified in the international multi-institutional dataset. To determine the survival benefit from lymphadenectomy, the therapeutic index was calculated by multiplying the frequency of LNM in a particular group of patients by the 3-year cancer-specific survival (CSS) rate of patients with LNM in that subgroup. Results: Among 471 patients who met the inclusion criteria, approximately half had LNM (n = 205, 43.5%). The median number of resected and metastatic LNs were 4 [interquartile range (IQR) 2-8] and 0 (IQR 0-1), respectively. Three-year CSS in the entire cohort was 29.9%, reflecting a therapeutic index value of 13.0. The therapeutic index was lower among patients with major vascular invasion (5.4), preoperative carcinoembryonic antigen (CEA) > 5.0 (8.2), and LNM in areas other than the hepatoduodenal ligament (5.2). Of note, a therapeutic index difference of more than 10 points was noted only when examining the number of LNs harvested [1-2 (4.1) vs. 3-6 (16.1) vs. ≥ 7 (17.8)]. Conclusion: The survival benefit derived from lymphadenectomy was poor among patients with major vascular invasion, CEA > 5.0, and LNM in areas other than the hepatoduodenal ligament. Resection of three or more LNs was associated with the highest therapeutic value among patients with LNM. | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Ann Surg Oncol. 2019 Sep;26(9):2959-2968. | pt_PT |
dc.identifier.doi | 10.1245/s10434-019-07483-9. | pt_PT |
dc.identifier.uri | http://hdl.handle.net/10400.17/3871 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Springer | pt_PT |
dc.subject | HCC CIR | pt_PT |
dc.subject | Aged | pt_PT |
dc.subject | Female | pt_PT |
dc.subject | Bile Duct Neoplasms / secondary | pt_PT |
dc.subject | Bile Duct Neoplasms / surgery* | pt_PT |
dc.subject | Cholangiocarcinoma / pathology | pt_PT |
dc.subject | Cholangiocarcinoma / surgery* | pt_PT |
dc.subject | Male | pt_PT |
dc.subject | Follow-Up Studies | pt_PT |
dc.subject | Hepatectomy / mortality* | pt_PT |
dc.subject | Humans | pt_PT |
dc.subject | Lymph Node Excision / mortality* | pt_PT |
dc.subject | Lymph Nodes / pathology* | pt_PT |
dc.subject | Midlle Aged | pt_PT |
dc.subject | Lymphatic Metastasis | pt_PT |
dc.subject | Neoplasm Staging | pt_PT |
dc.subject | Prognosis | pt_PT |
dc.subject | Survival Rate | pt_PT |
dc.subject | Therapeutic Index* | pt_PT |
dc.title | Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation? | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.endPage | 2968 | pt_PT |
oaire.citation.startPage | 2959 | pt_PT |
oaire.citation.title | Annals of Surgical Oncology | pt_PT |
oaire.citation.volume | 26 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Annals Surg Oncol 2019 2959.pdf
- Size:
- 315.55 KB
- Format:
- Adobe Portable Document Format